MURA (Mural Oncology plc) Stock Market Reviews

crown

search

Read and share opinions on MURA (Mural Oncology plc) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

MURA

Mural Oncology plc

clarify Biotechnology

bookmark Healthcare

public Ireland

Sell Neutral Buy

Latest News

XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
Nov 12, 2025
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
Oct 24, 2025
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting
Sep 23, 2025
Xoma, a drug royalty specialist, buys another ‘zombie’ biotech
Aug 20, 2025
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
Aug 20, 2025
Mural Oncology Announces Second Quarter Financial Results and Provides Business Update
Aug 4, 2025
Mural Oncology Announces Number of Relevant Securities in Issue
May 19, 2025
FORM 8.1(a) & (b) - Mural Oncology plc
Apr 30, 2025
Mural Oncology Announces Plans to Explore Strategic Alternatives
Apr 15, 2025
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
Mar 25, 2025
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Feb 18, 2025
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
Jan 9, 2025
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 3, 2024

Reviews